141 related articles for article (PubMed ID: 16247341)
1. Tipranavir (Aptivus) for HIV.
Med Lett Drugs Ther; 2005 Oct; 47(1219):83-4. PubMed ID: 16247341
[TBL] [Abstract][Full Text] [Related]
2. [Perspectives: hope for therapy experienced patients. Tipranavir shows superior effectiveness with comparable safety].
MMW Fortschr Med; 2005 Apr; 147 Spec No 1():44-5. PubMed ID: 16385873
[No Abstract] [Full Text] [Related]
3. Tipranavir: PNU 140690, tipranivir.
Drugs R D; 2006; 7(1):55-62. PubMed ID: 16620137
[TBL] [Abstract][Full Text] [Related]
4. Aptivus capsules granted full FDA approval.
AIDS Patient Care STDS; 2007 Nov; 21(11):889-90. PubMed ID: 18338430
[No Abstract] [Full Text] [Related]
5. New black box warning for ritonavir-boosted tipranavir.
Ryan CT
AIDS Clin Care; 2006 Aug; 18(8):72. PubMed ID: 16906669
[No Abstract] [Full Text] [Related]
6. Anti-HIV agents. Tipranavir in treatment-experienced PHAs.
TreatmentUpdate; 2005; 17(1):4-5. PubMed ID: 17225315
[No Abstract] [Full Text] [Related]
7. Tipranavir (Aptivus): approval cautiously recommended.
James JS
AIDS Treat News; 2005 May; (412):2-3. PubMed ID: 16047408
[TBL] [Abstract][Full Text] [Related]
8. [Desensitization to tipranavir caused by toxicodermia].
Martínez Castro B; Ferrando Piqueres R; Martínez García M; Soler Company E
Farm Hosp; 2009; 33(6):340-2. PubMed ID: 20038397
[No Abstract] [Full Text] [Related]
9. Tipranavir.
Gallant J
Drugs; 2003; 63(15):1619-20. PubMed ID: 12887269
[No Abstract] [Full Text] [Related]
10. Tipranavir: the first nonpeptidic protease inhibitor for the treatment of protease resistance.
Luna B; Townsend MU
Clin Ther; 2007 Nov; 29(11):2309-18. PubMed ID: 18158073
[TBL] [Abstract][Full Text] [Related]
11. Anti-HIV agents. Unexpected results from a tipranavir study.
TreatmentUpdate; 2004; 16(3):6-7. PubMed ID: 17216836
[No Abstract] [Full Text] [Related]
12. Aptivus in the hotseat. Excerpts from the FDA hearings.
Huff B
GMHC Treat Issues; 2005; 19(5-6):6-8. PubMed ID: 16193577
[No Abstract] [Full Text] [Related]
13. FDA approves Aptivus (tipranavir).
Pham PA
Hopkins HIV Rep; 2005 Jul; 17(4):6-7. PubMed ID: 16419308
[No Abstract] [Full Text] [Related]
14. Porphyria cutanea tarda in an HIV-1-infected patient after the initiation of tipranavir/ritonavir: case report.
Celesia BM; Onorante A; Nunnari G; Mughini MT; Mavilla S; Massimino SD; Russo R
AIDS; 2007 Jul; 21(11):1495-6. PubMed ID: 17589203
[No Abstract] [Full Text] [Related]
15. [New protease inhibitor for PI pretreated patients. Tipranavir targets also multiresistant viruses].
MMW Fortschr Med; 2004 Apr; 146 Spec No 1():60-1. PubMed ID: 15373052
[No Abstract] [Full Text] [Related]
16. Tipranavir: a new option for the treatment of drug-resistant HIV infection.
Temesgen Z; Feinberg J
Clin Infect Dis; 2007 Sep; 45(6):761-9. PubMed ID: 17712762
[TBL] [Abstract][Full Text] [Related]
17. New protease inhibitor offers clinicians hope for better salvage therapy.
Murphy MJ
HIV Clin; 2006; 18(1):1-3. PubMed ID: 16838417
[No Abstract] [Full Text] [Related]
18. Tipranavir: new drug. HIV protease inhibitor. A last resort.
Prescrire Int; 2006 Dec; 15(86):217-9. PubMed ID: 17167925
[TBL] [Abstract][Full Text] [Related]
19. FDA approval: tipranavir.
Sax PE
AIDS Clin Care; 2005 Aug; 17(8):78. PubMed ID: 16193574
[No Abstract] [Full Text] [Related]
20. Tipranavir: a protease inhibitor for HIV salvage therapy.
Dong BJ; Cocohoba JM
Ann Pharmacother; 2006; 40(7-8):1311-21. PubMed ID: 16788094
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
